230 related articles for article (PubMed ID: 28854900)
41. Evidence for post-translational processing of vascular endothelial (VE)-cadherin in brain tumors: towards a candidate biomarker.
Vilgrain I; Sidibé A; Polena H; Cand F; Mannic T; Arboleas M; Boccard S; Baudet A; Gulino-Debrac D; Bouillet L; Quesada JL; Mendoza C; Lebas JF; Pelletier L; Berger F
PLoS One; 2013; 8(12):e80056. PubMed ID: 24358106
[TBL] [Abstract][Full Text] [Related]
42. Prognostic significance of VEGF receptors expression on the tumor cells in skull base chordoma.
Morimoto Y; Tamura R; Ohara K; Kosugi K; Oishi Y; Kuranari Y; Yoshida K; Toda M
J Neurooncol; 2019 Aug; 144(1):65-77. PubMed ID: 31240525
[TBL] [Abstract][Full Text] [Related]
43. VE-cadherin increases the half-life of VEGF receptor 2.
Calera MR; Venkatakrishnan A; Kazlauskas A
Exp Cell Res; 2004 Oct; 300(1):248-56. PubMed ID: 15383331
[TBL] [Abstract][Full Text] [Related]
44. The role of differential VE-cadherin dynamics in cell rearrangement during angiogenesis.
Bentley K; Franco CA; Philippides A; Blanco R; Dierkes M; Gebala V; Stanchi F; Jones M; Aspalter IM; Cagna G; Weström S; Claesson-Welsh L; Vestweber D; Gerhardt H
Nat Cell Biol; 2014 Apr; 16(4):309-21. PubMed ID: 24658686
[TBL] [Abstract][Full Text] [Related]
45. Vasculogenic mimicry signaling revisited: focus on non-vascular VE-cadherin.
Delgado-Bellido D; Serrano-Saenz S; Fernández-Cortés M; Oliver FJ
Mol Cancer; 2017 Mar; 16(1):65. PubMed ID: 28320399
[TBL] [Abstract][Full Text] [Related]
46. Vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 expression in non-small cell lung cancer patients: relation to prognosis.
Bonnesen B; Pappot H; Holmstav J; Skov BG
Lung Cancer; 2009 Dec; 66(3):314-8. PubMed ID: 19324448
[TBL] [Abstract][Full Text] [Related]
47. Anti-HLA I antibodies induce VEGF production by endothelial cells, which increases proliferation and paracellular permeability.
Bieri M; Oroszlan M; Farkas A; Ligeti N; Bieri J; Mohacsi P
Int J Biochem Cell Biol; 2009 Dec; 41(12):2422-30. PubMed ID: 19577661
[TBL] [Abstract][Full Text] [Related]
48. Let-7a inhibits tumor cell growth and metastasis by directly targeting RTKN in human colon cancer.
Li B; Chen P; Chang Y; Qi J; Fu H; Guo H
Biochem Biophys Res Commun; 2016 Sep; 478(2):739-45. PubMed ID: 27498032
[TBL] [Abstract][Full Text] [Related]
49. Sunitinib but not VEGF blockade inhibits cancer stem cell endothelial differentiation.
Brossa A; Grange C; Mancuso L; Annaratone L; Satolli MA; Mazzone M; Camussi G; Bussolati B
Oncotarget; 2015 May; 6(13):11295-309. PubMed ID: 25948774
[TBL] [Abstract][Full Text] [Related]
50. Tumor necrosis factor-alpha damages tumor blood vessel integrity by targeting VE-cadherin.
Menon C; Ghartey A; Canter R; Feldman M; Fraker DL
Ann Surg; 2006 Nov; 244(5):781-91. PubMed ID: 17060772
[TBL] [Abstract][Full Text] [Related]
51. Human mature endothelial cells modulate peripheral blood mononuclear cell differentiation toward an endothelial phenotype.
Bellik L; Musilli C; Vinci MC; Ledda F; Parenti A
Exp Cell Res; 2008 Oct; 314(16):2965-74. PubMed ID: 18692498
[TBL] [Abstract][Full Text] [Related]
52. VE-Cadherin-mediated cell-cell interaction suppresses sprouting via signaling to MLC2 phosphorylation.
Abraham S; Yeo M; Montero-Balaguer M; Paterson H; Dejana E; Marshall CJ; Mavria G
Curr Biol; 2009 Apr; 19(8):668-74. PubMed ID: 19345098
[TBL] [Abstract][Full Text] [Related]
53. Nef-M1, a peptide antagonist of CXCR4, inhibits tumor angiogenesis and epithelial‑to‑mesenchymal transition in colon and breast cancers.
Katkoori VR; Basson MD; Bond VC; Manne U; Bumpers HL
Oncotarget; 2015 Sep; 6(29):27763-77. PubMed ID: 26318034
[TBL] [Abstract][Full Text] [Related]
54. Activated VEGFR2/KDR pathway in tumour cells and tumour associated vessels of colorectal cancer.
Giatromanolaki A; Koukourakis MI; Sivridis E; Chlouverakis G; Vourvouhaki E; Turley H; Harris AL; Gatter KC
Eur J Clin Invest; 2007 Nov; 37(11):878-86. PubMed ID: 17883421
[TBL] [Abstract][Full Text] [Related]
55. Maintenance of Clonogenic KIT(+) Human Colon Tumor Cells Requires Secretion of Stem Cell Factor by Differentiated Tumor Cells.
Fatrai S; van Schelven SJ; Ubink I; Govaert KM; Raats D; Koster J; Verheem A; Borel Rinkes IH; Kranenburg O
Gastroenterology; 2015 Sep; 149(3):692-704. PubMed ID: 25962936
[TBL] [Abstract][Full Text] [Related]
56. Over expression of galectin-3 associates with short-term poor prognosis in stage II colon cancer.
Huang Z; Ai Z; Li N; Xi H; Gao X; Wang F; Tan X; Liu H
Cancer Biomark; 2016; 17(4):445-455. PubMed ID: 28085015
[TBL] [Abstract][Full Text] [Related]
57. Positive expression of LSD1 and negative expression of E-cadherin correlate with metastasis and poor prognosis of colon cancer.
Jie D; Zhongmin Z; Guoqing L; Sheng L; Yi Z; Jing W; Liang Z
Dig Dis Sci; 2013 Jun; 58(6):1581-9. PubMed ID: 23314859
[TBL] [Abstract][Full Text] [Related]
58. Treatment of cancer stem cells from human colon adenocarcinoma cell line HT-29 with resveratrol and sulindac induced mesenchymal-endothelial transition rate.
Pouyafar A; Rezabakhsh A; Rahbarghazi R; Heydarabad MZ; Shokrollahi E; Sokullu E; Khaksar M; Nourazarian A; Avci ÇB
Cell Tissue Res; 2019 Jun; 376(3):377-388. PubMed ID: 30758710
[TBL] [Abstract][Full Text] [Related]
59. Vascular endothelial growth factor receptor 2 as a marker for malignant vascular tumors and mesothelioma: an immunohistochemical study of 262 vascular endothelial and 1640 nonvascular tumors.
Miettinen M; Rikala MS; Rys J; Lasota J; Wang ZF
Am J Surg Pathol; 2012 Apr; 36(4):629-39. PubMed ID: 22314185
[TBL] [Abstract][Full Text] [Related]
60. VE-cadherin-independent cancer cell incorporation into the vascular endothelium precedes transmigration.
Hamilla SM; Stroka KM; Aranda-Espinoza H
PLoS One; 2014; 9(10):e109748. PubMed ID: 25275457
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
